(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Monetary Wellness: Planning Tips for Independence from the rat race - 2Party Urban communities of the World
- 3Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- 4Becoming amazing at Arranging Pay Raises
- 5Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
- 6 Modest and Strong Tire Brands
- The 15 Most Rousing TED Chats on Self-awareness
- Favored Organic product for Seniors' Prosperity: Make Your Determination
- Best Amusement Park Bite: What Do You Very much want to Crunch On?
- The Most Famous Virtual Entertainment Powerhouses of the Year
- 6 Nations for Setting up camp
- Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- Independence from the rat race for Recent college grads: Systems and Tips
- 3D Printers for Specialists
